Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22

1.

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.

Heo J, Reid T, Ruo L, Breitbach CJ, Rose S, Bloomston M, Cho M, Lim HY, Chung HC, Kim CW, Burke J, Lencioni R, Hickman T, Moon A, Lee YS, Kim MK, Daneshmand M, Dubois K, Longpre L, Ngo M, Rooney C, Bell JC, Rhee BG, Patt R, Hwang TH, Kirn DH.

Nat Med. 2013 Mar;19(3):329-36. doi: 10.1038/nm.3089. Epub 2013 Feb 10.

2.

The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).

Breitbach CJ, Bell JC, Hwang TH, Kirn DH, Burke J.

Oncolytic Virother. 2015 Jan 28;4:25-31. doi: 10.2147/OV.S59640. eCollection 2015. Review.

3.

Oncolytic vaccinia virus for the treatment of cancer.

Guse K, Cerullo V, Hemminki A.

Expert Opin Biol Ther. 2011 May;11(5):595-608. doi: 10.1517/14712598.2011.558838. Epub 2011 Feb 22. Review.

PMID:
21338330
4.

JX-594, a targeted oncolytic poxvirus for the treatment of cancer.

Merrick AE, Ilett EJ, Melcher AA.

Curr Opin Investig Drugs. 2009 Dec;10(12):1372-82. Review.

PMID:
19943208
5.

Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.

Breitbach CJ, Parato K, Burke J, Hwang TH, Bell JC, Kirn DH.

Curr Opin Virol. 2015 Aug;13:49-54. doi: 10.1016/j.coviro.2015.03.016. Epub 2015 Apr 17. Review.

PMID:
25900822
6.

Targeted and armed oncolytic poxviruses for cancer: the lead example of JX-594.

Breitbach CJ, Thorne SH, Bell JC, Kirn DH.

Curr Pharm Biotechnol. 2012 Jul;13(9):1768-72. Review.

PMID:
21740365
7.

Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma.

Jebar AH, Errington-Mais F, Vile RG, Selby PJ, Melcher AA, Griffin S.

J Gen Virol. 2015 Jul;96(Pt 7):1533-50. doi: 10.1099/vir.0.000098. Epub 2015 Feb 23. Review.

PMID:
25711964
8.

Oncolytic virus therapy: A new era of cancer treatment at dawn.

Fukuhara H, Ino Y, Todo T.

Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Review.

9.

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy.

Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, Kaufman HL.

Expert Rev Anticancer Ther. 2015;15(12):1389-403. doi: 10.1586/14737140.2015.1115725. Review.

PMID:
26558498
10.

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.

Kohlhapp FJ, Kaufman HL.

Clin Cancer Res. 2016 Mar 1;22(5):1048-54. doi: 10.1158/1078-0432.CCR-15-2667. Epub 2015 Dec 30. Review.

11.

Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.

Bommareddy PK, Patel A, Hossain S, Kaufman HL.

Am J Clin Dermatol. 2017 Feb;18(1):1-15. doi: 10.1007/s40257-016-0238-9. Review.

PMID:
27988837
12.

Immunotherapeutic potential of oncolytic vaccinia virus.

Thorne SH.

Immunol Res. 2011 Aug;50(2-3):286-93. doi: 10.1007/s12026-011-8211-4. Review.

PMID:
21717084
13.

The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma.

El-Khoueiry A.

Am Soc Clin Oncol Educ Book. 2017;37:311-317. doi: 10.14694/EDBK_175230. Review.

14.

Oncolytic immunotherapy: unlocking the potential of viruses to help target cancer.

Hamid O, Hoffner B, Gasal E, Hong J, Carvajal RD.

Cancer Immunol Immunother. 2017 Oct;66(10):1249-1264. doi: 10.1007/s00262-017-2025-8. Epub 2017 Jul 15. Review.

15.

Perspectives of immunotherapy in hepatocellular carcinoma (HCC).

Büttner N, Schmidt N, Thimme R.

Z Gastroenterol. 2016 Dec;54(12):1334-1342. Epub 2016 Dec 9. Review.

PMID:
27936483
16.

Herpes simplex virus oncolytic vaccine therapy in melanoma.

Sivendran S, Pan M, Kaufman HL, Saenger Y.

Expert Opin Biol Ther. 2010 Jul;10(7):1145-53. doi: 10.1517/14712598.2010.495383. Review.

PMID:
20515292
17.

Immunotherapy in hepatocellular carcinoma: Primed to make a difference?

Harding JJ, El Dika I, Abou-Alfa GK.

Cancer. 2016 Feb 1;122(3):367-77. doi: 10.1002/cncr.29769. Epub 2015 Nov 5. Review.

18.

Immunobiology of hepatocellular carcinoma.

Flecken T, Spangenberg HC, Thimme R.

Langenbecks Arch Surg. 2012 Jun;397(5):673-80. doi: 10.1007/s00423-011-0783-x. Epub 2011 Apr 9. Review.

PMID:
21479622
19.

Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.

Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J.

Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. Review.

20.

Trial Watch-Oncolytic viruses and cancer therapy.

Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1117740. eCollection 2016 Feb. Review.

Supplemental Content

Support Center